Tumour angiogenesis: The relevance to surgeons

Annals of the Royal College of Surgeons of England

Volumn 88, Issue 6, 2006, Pages 525-529

  Atkin, G K ^a   Chopada, Abhay ^a  

^a EALING HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

Angiogenesis inhibitors; Neovascularisation; Surgery

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPTOPRIL; DEXAMETHASONE; DICLOFENAC; ENDOSTATIN; INDOMETACIN; PLASMID VECTOR; RECOMBINANT PROTEIN; TAMOXIFEN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DNA VECTOR; DRUG MECHANISM; DRUG SAFETY; EDEMA; FACTORIAL ANALYSIS; HISTOPATHOLOGY; HOST CELL; HUMAN; INFORMATION RETRIEVAL; MALIGNANT TRANSFORMATION; MEDICAL INFORMATION; MEDICAL LITERATURE; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT CARE; PROGNOSIS; REVIEW; SURGEON; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INFECTION; WOUND HEALING;

ANGIOGENESIS INHIBITORS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POSTOPERATIVE COMPLICATIONS;

EID: 33750149320     PISSN: 00358843     EISSN: None     Source Type: Journal    
DOI: 10.1308/003588406X117106     Document Type: Review

References (40)

1. Noden DM. Embryonic origins and assembly of blood vessels. Am Rev Respir Dis 1989; 140: 1097-103.
2. Ellis LM, Liu W, Ahmad SA, Fan F, Jung YD, Shaheen RM et al. Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin Oncol 2001; 28 (Suppl 16): 94-104.
3. Li WW. Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. Acad Radiol 2000; 7: 800-11.
4. McNamara DA, Harmey JH, Walsh TN, Redmond HP, Bouchier-Hayes DJ. Significance of angiogenesis in cancer therapy. Br J Surg 1998; 85: 1044-55.
5. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266: 11947-54.
6. Boedefeld 2nd WM, Bland KI, Heslin MJ. Recent insights into angiogenesis, apoptosis, invasion, and metastasis in colorectal carcinoma. Ann Surg Oncol 2003; 10: 839-51.
7. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995; 36: 127-37.
8. Bikfalvi A, Bicknell R. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol Sci 2002; 23: 576-82.
9. Nor JE, Christensen J, Mooney DJ, Polverini PJ. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999; 154: 375-84.
10. O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 2000; 156: 393-8.
11. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991; 181: 902-6.
12. Zetter BR. Migration of capillary endothelial cells is stimulated by tumour-derived factors. Nature 1980; 285: 41-3.
13. Darland DC, D'Amore PA. Blood vessel maturation: vascular development comes of age. J Clin Invest 1999; 103: 157-8.
14. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
15. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
16. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
17. Poon RT, Fan ST, Wong J. Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches. Ann Surg 2003; 238: 9-28.
18. Rak J, Filmus J, Kerbel RS. Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer 1996; 32A: 2438-50.
19. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002; 20: 3906-27.
20. Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D et al. Combined therapy with direct and indirect angiogenesis inhibition results in enchanced antiangiogenic and antitumor effects. Cancer Res 2003; 63: 8890-8.
21. Scappaticci FA, Smith R, Pathak A, Schloss D, Lurn B, Cao Y et al. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Ther 2001; 3: 186-96.
22. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61: 3369-72.
23. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394: 287-91.
24. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med 2002; 136: 54-71.
25. Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy; the PREVENT single-centre, randomised, controlled trial. Lancet 1999; 354: 1493-8.
26. Epstein SE, Kornowski R, Fuchs S, Dvorak HF. Angiogeness therapy: amidst the hype, the neglected potential for serious side effects. Circulation 2001; 104: 115-9.
27. Freedman SB. Clinical trials of gene therapy for atherosclerotic cardiovascular disease. Curr Opin Lipidol 2002; 13: 653-61.
28. Ferber D. Gene therapy. Safer and virus-free? Science 2001; 294: 1638-42.
29. Murthy MS, Scanlon EF, Silverman RH, Goodheart CR, Goldschmidt RA, Jelachich ML. The role of fibronectin in tumor implantation at surgical sites. Clin Exp Metastasis 1993; 11: 159-73.
30. Hofer SO, Molema G, Hermens RA, Wanebo HJ, Reichner JS, Hoekstra HJ. The effect of surgical wounding on tumour development. Eur J Surg Oncol 1999; 25: 231-43.
31. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-92.
32. van der Bilt JD, Borel Rinkes IH. Surgery and angiogenesis. Biochim Biophys Acta 2004; 1654: 95-104.
33. Picardo A, Karpoff HM, Ng B, Lee J, Brennan MF, Fong Y. Partial hepatectomy accelerates local tumor growth: potential roles of local cytokine activation. Surgery 1998; 124: 57-64.
34. Hendriks JM, Hubens G, Wuyts FL, Vermeulen P, Hubens A, Eyskens E. Experimental study of intraperitoneal suramin on the healing of colonic anastomoses. Br J Surg 1999; 86: 1171-5.
35. George ML, Dzik-Jurasz AS, Padhani AR, Brown G, Tait DM, Eccles SA et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg 2001; 88: 1628-36.
36. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388-93.
37. Cheng WF, Lee CN, Chu JS, Chen CA, Chen TM, Shau WY et al. Vascularity index as a novel parameter for the in vivo assessment of angiogenesis in patients with cervical carcinoma. Cancer 1999; 85: 651-7.
38. Blankenberg FG, Eckelman WC, Strauss HW, Welch MJ, Alavi A, Anderson C et al. Role of radionuclide imaging in trials of antiangiogenic therapy. Acad Radiol 2000; 7: 851-67.
39. Lehtio K, Eskola O, Viljanen T, Oikonen V, Gronroos T, Sillanmaki L et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004; 59: 971-82.
40. 18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer 2004; 90: 2232-42.